Raquel López Mejías

Dr. Raquel López Mejías

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LCLorenzo Cavagna
Lorenzo Cavagna
ETErnesto Trallero-Araguás
Ernesto Trallero-Araguás
FMFederica Meloni
Federica Meloni
Ilaria CavazzanaIlaria Cavazzana
Ilaria Cavazzana
JRJorge Rojas-Serrano
Jorge Rojas-Serrano
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Antisynthetase syndrome (ASSD) is a rare clinical condition that is characterized by the occurrence of a classic clinical triad, encompassing myositis, arthritis, and interstitial lung disease (ILD), along with specific autoantibodies that are addressed to different aminoacyl tRNA synthetases (ARS). Until now, it has been unknown whether the presence of a different ARS might affect the clinical presentation, evolution, and outcome of ASSD. In this study, we retrospectively recorded the time of onset, characteristics, clustering of triad findings, and survival of 828 ASSD patients (593 anti-Jo1, 95 anti-PL7, 84 anti-PL12, 38 anti-EJ, and 18 anti-OJ), referring to AENEAS (American and European NEtwork of Antisynthetase Syndrome) collaborative group’s cohort. Comparisons were performed first between all ARS cases and then, in the case of significance, while using anti-Jo1 positive patients as the reference group. The characteristics of triad findings were similar and the onset mainly began with a single triad finding in all groups despite some differences in overall prevalence. The “ex-novo” occurrence of triad findings was only reduced in the anti-PL12-positive cohort, however, it occurred in a clinically relevant percentage of patients (30%). Moreover, survival was not influenced by the underlying anti-aminoacyl tRNA synthetase antibodies’ positivity, which confirmed that antisynthetase syndrome is a heterogeneous condition and that antibody specificity only partially influences the clinical presentation and evolution of this condition.

1 March 2018 in Autoimmunity Reviews
Verified
Journal Article
Open access
Raquel López MejíasRaquel López Mejías
Raquel López Mejías
Santos CastañedaSantos Castañeda
Santos Castañeda
FGFernanda Genre
Fernanda Genre
SRSara Remuzgo-Martínez
Sara Remuzgo-Martínez
F. David CarmonaF. David Carmona
F. David Carmona
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Immunoglobulin-A vasculitis (IgAV) is classically a childhood small-sized blood vessel vasculitis with predominant involvement of the skin. Gastrointestinal and joint manifestations are common in patients diagnosed with this condition. Nephritis, which is more severe in adults, constitutes the most feared complication of this vasculitis. The molecular bases underlying the origin of IgAV have not been completely elucidated. Nevertheless, several pieces of evidence support the claim that genes play a crucial role in the pathogenesis of this disease. The human leukocyte antigen (HLA) region is, until now, the main genetic factor associated with IgAV pathogenesis. Besides a strong association with HLA class II alleles, specifically HLA-DRB1 alleles, HLA class I alleles also seem to influence on the predisposition of this disease. Other gene polymorphisms located outside the HLA region, including those coding cytokines, chemokines, adhesion molecules as well as those related to T-cells, aberrant glycosylation of IgA1, nitric oxide production, neoangiogenesis, renin-angiotensin system and lipid, Pyrin and homocysteine metabolism, may be implicated not only in the predisposition to IgAV but also in its severity. An update of the current knowledge of the genetic component associated with the pathogenesis of IgAV is detailed in this review.

11 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Raquel López MejíasRaquel López Mejías
Raquel López Mejías
F. David CarmonaF. David Carmona
F. David Carmona
Santos CastañedaSantos Castañeda
Santos Castañeda
FGFernanda Genre
Fernanda Genre
SRSara Remuzgo-Martínez
Sara Remuzgo-Martínez
MGMiguel A. González-Gay
Miguel A. González-Gay
The genetic component of Immunoglobulin-A (IgA) vasculitis is still far to be elucidated. To increase the current knowledge on the genetic component of this vasculitis we performed the first genome-wide association study (GWAS) on this condition. 308 IgA vasculitis patients and 1,018 healthy controls from Spain were genotyped by Illumina HumanCore BeadChips. Imputation of GWAS data was performed using the 1000 Genomes Project Phase III dataset as reference panel. After quality control filters and GWAS imputation, 285 patients and 1,006 controls remained in the datasets and were included in further analysis. Additionally, the human leukocyte antigen (HLA) region was comprehensively studied by imputing classical alleles and polymorphic amino acid positions. A linkage disequilibrium block of polymorphisms located in the HLA class II region surpassed the genome-wide level of significance (OR = 0.56, 95% CI = 0.46–0.68). Although no polymorphic amino acid positions were associated at the genome-wide level of significance, P-values of potential relevance were observed for the positions 13 and 11 of HLA-DRB1 (P = 6.67E-05, P = 1.88E-05, respectively). Outside the HLA, potential associations were detected, but none of them were close to the statistical significance. In conclusion, our study suggests that IgA vasculitis is an archetypal HLA class II disease.

24 June 2019 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
Raquel López MejíasRaquel López Mejías
Raquel López Mejías
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay

14 April 2015 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
Raquel López MejíasRaquel López Mejías
Raquel López Mejías
FGFernanda Genre
Fernanda Genre
BPBelén Sevilla Pérez
Belén Sevilla Pérez
Santos CastañedaSantos Castañeda
Santos Castañeda
NONorberto Ortego-Centeno
Norberto Ortego-Centeno
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
Introduction: A study was conducted to determine whether the human leukocyte antigen (HLA) B alleles are implicated in the susceptibility to Henoch-Schönlein purpura (HSP) in the largest series of Caucasian HSP patients ever assessed for genetic studies. Methods: The study population was composed of 349 Spanish patients diagnosed with HSP fulfilling the American College of Rheumatology and the Michel et al. classification criteria, and 335 sex and ethnically matched controls. HLA-B phenotypes were determined by sequencing-based typing (SBT) and analyzed by chi-square or Fisher exact test. Results: A statistically significant increase of HLA-B*41:02 allele in HSP patients when compared with controls was found (8.3% versus 1.5% respectively; P = 0.0001; OR (odds ratio) =5.76 [2.15-19.3]). These results remained statistically significant after adjusting for Bonferroni correction (P = 0.0028). An internal validation also confirmed the susceptibility effect on HSP associated with HLA-B*41:02 (OR = 5.70 [1.98-16.44]). Since a former study described an association between HLA-DRB1*01:03 and HSP susceptibility, we also evaluated the implication of HLA-B*41:02 independently of HLA-DRB1*01:03. Interestingly, the association remained statistically significant (P = 0.0004, OR = 4.97 [1.8-16.9]). No HLA-B association with specific HSP clinical features was found. Conclusions: Our study indicates that HLA-B*41:02 is associated with the susceptibility to HSP in Spanish patients irrespective of HLA-DRB1 status.

Verified
Journal Article
Open access
PDF file
VCVerónics Pulito Cueto
Verónics Pulito Cueto
FGFernanda Genre
Fernanda Genre
Raquel López MejíasRaquel López Mejías
Raquel López Mejías
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
DFDavid Iturbe Fernández
David Iturbe Fernández
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
The aim of this study was to determine the role of endothelin-1 (ET-1), a molecule involved in multiple vascular and fibrosing abnormalities, as a biomarker of interstitial lung disease (ILD), as well as its use for the differential diagnosis between idiopathic pulmonary fibrosis (IPF) and ILD associated with autoimmune diseases (AD-ILD), using a large and well-defined cohort of patients with ILD. A total of 112 patients with IPF, 91 patients with AD-ILD (28 rheumatoid arthritis (RA), 26 systemic sclerosis, 20 idiopathic inflammatory myositis and 17 interstitial pneumonia with autoimmune features) and 44 healthy controls were included. ET-1 serum levels were determined by enzyme-linked immunosorbent assay. A significant increase in ET-1 levels was found in patients with IPF compared to controls. Likewise, AD-ILD patients also showed higher ET-1 levels than controls when the whole cohort was stratified by the type of AD. Similar ET-1 levels were found in IPF and AD-ILD patients, regardless of the underlying AD. Interestingly, increased ET-1 levels were correlated with worse lung function in IPF and RA-ILD patients. Our study supports that serum ET-1 may be useful as a biomarker of ILD, although it could not help in the differential diagnosis between IPF and AD-ILD. Moreover, ET-1 levels may be associated with ILD severity.